Comparative Evaluation of Six SARS-CoV-2 Real-Time RT-PCR Diagnostic Approaches Shows Substantial Genomic Variant-Dependent Intra- and Inter-Test Variability, Poor Interchangeability of Cycle Threshold and Complementary Turn-Around Times.
Ct value
coronavirus disease 19 (COVID-19)
genomic variant
real-time RT-PCR
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
turn-around time
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
12 Apr 2022
12 Apr 2022
Historique:
received:
04
03
2022
revised:
30
03
2022
accepted:
10
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Several professional societies advise against using real-time Reverse-Transcription PCR (rtRT-PCR) cycle threshold (Ct) values to guide clinical decisions. We comparatively assessed the variability of Ct values generated by six diagnostic approaches by testing serial dilutions of well-characterized isolates of 10 clinically most relevant SARS-CoV-2 genomic variants: Alpha, Beta, Gamma, Delta, Eta, Iota, Omicron, A.27, B.1.258.17, and B.1 with D614G mutation. Comparison of three fully automated rtRT-PCR analyzers and a reference manual rtRT-PCR assay using RNA isolated with three different nucleic acid isolation instruments showed substantial inter-variant intra-test and intra-variant inter-test variability. Ct value differences were dependent on both the rtRT-PCR platform and SARS-CoV-2 genomic variant. Differences ranging from 2.0 to 8.4 Ct values were observed when testing equal concentrations of different SARS-CoV-2 variants. Results confirm that Ct values are an unreliable surrogate for viral load and should not be used as a proxy of infectivity and transmissibility, especially when different rtRT-PCR assays are used in parallel and multiple SARS-CoV-2 variants are circulating. A detailed turn-around time (TAT) comparative assessment showed substantially different TATs, but parallel use of different diagnostic approaches was beneficial and complementary, allowing release of results for more than 81% of non-priority samples within 8 h after admission.
Identifiants
pubmed: 35456137
pii: pathogens11040462
doi: 10.3390/pathogens11040462
pmc: PMC9029830
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Slovenian Research Agency
ID : P3-0083 and V3-2034
Organisme : European Virus Archive - GLOBAL project, which has received funding from the European Union's Horizon 2020
ID : 871029
Organisme : Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana
ID : N/A
Références
Euro Surveill. 2020 Apr;25(14):
pubmed: 32290902
Viruses. 2021 Aug 25;13(9):
pubmed: 34578269
J Virol Methods. 2021 Oct;296:114217
pubmed: 34171343
BMJ Case Rep. 2021 Jul 27;14(7):
pubmed: 34315745
Clin Chem. 2020 Jul 1;66(7):975-977
pubmed: 32315390
J Virol Methods. 2021 May;291:114086
pubmed: 33577957
Obstet Gynecol. 2020 Oct;136(4):838-841
pubmed: 32701763
J Infect Public Health. 2021 Sep;14(9):1201-1205
pubmed: 34416598
Infect Dis Rep. 2021 Jul 16;13(3):645-653
pubmed: 34287354
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32518072
J Virol Methods. 2013 Nov;193(2):565-71
pubmed: 23748121
Int J Infect Dis. 2021 Dec;113:207-209
pubmed: 34628023
PLoS Biol. 2020 Oct 7;18(10):e3000867
pubmed: 33027248
Front Cell Infect Microbiol. 2021 Jun 10;11:630552
pubmed: 34178716
J Clin Virol. 2021 Jun;139:104820
pubmed: 33865031
Emerg Infect Dis. 2020 Jul;26(7):1633-1635
pubmed: 32294051
Diagn Microbiol Infect Dis. 2021 Jul;100(3):115366
pubmed: 33756311
Lancet. 2020 Apr 25;395(10233):1339-1340
pubmed: 32304647
Clin Chem Lab Med. 2020 Dec 16;59(5):987-994
pubmed: 33554519
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
J Virol Methods. 2021 Jul;293:114149
pubmed: 33839185
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33468607
J Med Virol. 2022 Jan;94(1):240-245
pubmed: 34460115
Int J Infect Dis. 2021 Jan;102:299-302
pubmed: 33130202
J Mol Diagn. 2021 Aug;23(8):920-928
pubmed: 34020039
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
J Med Virol. 2021 Dec;93(12):6794-6797
pubmed: 34264527
Diagnostics (Basel). 2021 Jun 15;11(6):
pubmed: 34203738
EClinicalMedicine. 2021 Sep;39:101082
pubmed: 34458708
Clin Microbiol Infect. 2021 Sep;27(9):1353.e1-1353.e5
pubmed: 34044153
Int J Mol Sci. 2021 Jan 28;22(3):
pubmed: 33525651
PLoS One. 2021 Sep 2;16(9):e0256877
pubmed: 34473769
Diagn Microbiol Infect Dis. 2021 Dec;101(4):115491
pubmed: 34464903
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
Nat Biomed Eng. 2020 Dec;4(12):1159-1167
pubmed: 33273713
Trends Biotechnol. 2020 Jun;38(6):637-649
pubmed: 31918858
Biosens Bioelectron. 2020 Oct 1;165:112454
pubmed: 32729549
World J Crit Care Med. 2021 Jul 9;10(4):132-150
pubmed: 34316448
Ann Saudi Med. 2020 Sep-Oct;40(5):373-381
pubmed: 32954791
Viruses. 2021 Jul 27;13(8):
pubmed: 34452325
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32277022
Sci Rep. 2021 Jan 12;11(1):780
pubmed: 33436939
Emerg Microbes Infect. 2020 Dec;9(1):747-756
pubmed: 32196430
Diagnostics (Basel). 2020 Jun 11;10(6):
pubmed: 32545412
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794447